A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, randomized, four-way crossover study. Subjects will
receive the four study treatments once, followed by in-clinic monitoring and extensive
pharmacokinetic analysis. Dosing occurs ~48 hours apart from patch application, in randomized
order. Subjects will have final assessment and be dismissed from the study.